INNOVIVA, INC. Payments to Acquire Long-term Investments
INNOVIVA, INC. (INVA) reported Payments to Acquire Long-term Investments of $17.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireLongtermInvestments · last filed 2026-02-25
- INNOVIVA, INC. payments to acquire long-term investments for the quarter ending 2024-12-31 was $0.00.
- INNOVIVA, INC. payments to acquire long-term investments for the quarter ending 2024-09-30 was $0.00.
- INNOVIVA, INC. payments to acquire long-term investments for the quarter ending 2024-06-30 was $0.00.
- INNOVIVA, INC. payments to acquire long-term investments for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- INNOVIVA, INC. payments to acquire long-term investments for fiscal 2025 was $17.50M.
- INNOVIVA, INC. payments to acquire long-term investments for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- INNOVIVA, INC. payments to acquire long-term investments for fiscal 2023 was $1.22M, a 91.13% decline from fiscal 2022.
- INNOVIVA, INC. payments to acquire long-term investments for fiscal 2022 was $13.72M, a 115.36% increase from fiscal 2021.
| Period end | Payments to Acquire Long-term Investments 3 month | Payments to Acquire Long-term Investments 3 month as first filed | Payments to Acquire Long-term Investments 6 month | Payments to Acquire Long-term Investments 6 month as first filed | Payments to Acquire Long-term Investments 9 month | Payments to Acquire Long-term Investments 9 month as first filed | Payments to Acquire Long-term Investments 12 month | Payments to Acquire Long-term Investments 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $17.50M 10-K · filed 2026-02-25 | |||||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $0.00 10-Q · filed 2024-07-31 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | -$34.47M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | -$34.47M derived: sum of 3 quarters · filed 2026-02-25 | -$34.47M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$34.47M derived: sum of 2 quarters · filed 2026-02-25 | -$34.47M derived: sum of 3 quarters · filed 2026-02-25 | $1.22M 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | -$34.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$34.47M derived: sum of 2 quarters · filed 2024-11-06 | $1.22M 10-Q · filed 2024-11-06 | $1.22M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $35.69M 10-Q · filed 2024-07-31 | $35.69M derived: sum of 3 quarters · filed 2025-02-26 | $35.69M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-03-31 | $35.69M 10-Q · filed 2024-05-08 | $35.69M derived: sum of 2 quarters · filed 2025-02-26 | $35.69M derived: sum of 3 quarters · filed 2025-02-26 | $38.20M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$1.00K derived: sum of 2 quarters · filed 2025-02-26 | $2.51M derived: sum of 3 quarters · filed 2025-02-26 | $13.72M 10-K · filed 2025-02-26 | $58.73M 10-K · filed 2023-02-28 | |||
| 2022-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $2.51M derived: sum of 2 quarters · filed 2023-11-01 | $13.72M 10-Q · filed 2023-11-01 | $58.73M 10-Q · filed 2022-11-09 | -$26.27M derived: sum of 4 quarters · filed 2024-03-05 | |||
| 2022-06-30 | $2.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $13.73M 10-Q · filed 2023-08-02 | $58.73M 10-Q · filed 2022-07-27 | -$26.27M derived: sum of 3 quarters · filed 2024-03-05 | -$26.27M derived: sum of 4 quarters · filed 2024-03-05 | |||
| 2022-03-31 | $11.22M 10-Q · filed 2023-05-09 | $56.22M 10-Q · filed 2022-05-05 | -$28.78M derived: sum of 2 quarters · filed 2024-03-05 | -$28.78M derived: sum of 3 quarters · filed 2024-03-05 | -$8.80M derived: sum of 4 quarters · filed 2024-03-05 | |||
| 2021-12-31 | -$40.00M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-05 | -$40.00M derived: sum of 2 quarters · filed 2024-03-05 | -$20.02M derived: sum of 3 quarters · filed 2024-03-05 | $6.37M 10-K/A · filed 2024-03-05 | $66.28M 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $19.98M derived: sum of 2 quarters · filed 2022-11-09 | $46.37M 10-Q · filed 2022-11-09 | $61.85M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | $19.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $46.37M 10-Q · filed 2022-07-27 | $61.85M derived: sum of 3 quarters · filed 2023-02-28 | $74.35M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | $26.39M 10-Q · filed 2022-05-05 | $41.88M derived: sum of 2 quarters · filed 2023-02-28 | $54.38M derived: sum of 3 quarters · filed 2023-02-28 | $89.38M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $15.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $27.98M derived: sum of 2 quarters · filed 2023-02-28 | $62.98M derived: sum of 3 quarters · filed 2023-02-28 | $87.98M 10-K · filed 2023-02-28 | $387.98M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $12.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | $47.50M derived: sum of 2 quarters · filed 2021-10-27 | $72.50M 10-Q · filed 2021-10-27 | $72.50M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2020-06-30 | $35.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $60.00M 10-Q · filed 2021-07-29 | $60.00M derived: sum of 3 quarters · filed 2022-03-17 | $60.00M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2020-03-31 | $25.00M 10-Q · filed 2021-04-28 | $25.00M derived: sum of 2 quarters · filed 2022-03-17 | $25.00M derived: sum of 3 quarters · filed 2022-03-17 | $25.00M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2019-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | $0.00 derived: sum of 3 quarters · filed 2022-03-17 | $0.00 10-K/A · filed 2022-03-17 | ||||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $0.00 derived: sum of 2 quarters · filed 2020-10-28 | $0.00 10-Q · filed 2020-10-28 | |||||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $0.00 10-Q · filed 2020-07-29 | ||||||
| 2019-03-31 | $0.00 10-Q · filed 2020-04-29 | |||||||
| 2018-12-31 | $0.00 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |